Serum Uric Acid Concentration in Patients with Polycystic Ovary Syndrome Treated by Metformin
Abstract
Background: Serum uric acid levels have emerged as a cardiovascular risk factor, and interventions aimed to decrease its level have been related with an improvement in clinical and non-clinical cardiovascular outcomes. This is particularly strong among persons at high cardiovascular risk, including those with hypertension, diabetes or polycystic ovary syndrome (PCOS). The studies about the effect of metformin on serum uric acid in patients with PCOS are very scarce at least in our locality. Objective: To evaluate the effect of metformin on serum uric acid concentration as non-classical cardiovascular risk factor in patients with PCOS in Mosul City in Iraq. Design: Case control study, Study Period: From 1 st of November 2010 and 1 st April 2011. Patients & Methods: A group of 40 women with PCOS of reproductive age who used metformin for more than three months (metformin users), with another age- and body mass index (BMI)-matched group of 52 women with PCOS who did not use metformin (metformin non-users), were included in this study. From each patient, a 5 ml blood sample was taken. The serum was used to measure the S.UA level using commercially available kit. BMI calculated as weight in kilograms divided by the squared height in meters. Results: This study revealed a significant lower levels of serum uric acid (P = 0.045) in metformin users as compared with metformin non-users and the serum uric acid levels were significantly correlated with BMI (r = 0.326, P = 0.001),…
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.